Skip to main content

Bevacizumab (International)

In the US, Bevacizumab (bevacizumab systemic) is a member of the drug class VEGF/VEGFR inhibitors and is used to treat Breast Cancer, Breast Cancer - Metastatic, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme, Hepatocellular Carcinoma, Macular Degeneration, Malignant Glioma, Neurofibromatosis, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Renal Cell Carcinoma and Solid Tumors.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Therapeutic Categories

Antineoplastic agent

Monoclonal antibody

Angiogenesis inhibitor

Vascular endothelial growth factor (VEGF) antagonist

Chemical Name

Immunoglobulin G1 (human-mouse monoclonal rhuMAb-VEGF gamma-chain anti-human vascular endothelial growth factor), disulfide with human-mouse monoclonal rhuMab-VEGF light chain, dimer (WHO )

Foreign Names

Generic Names

Brand Names


ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.